Serum omentin-1 and risk of one-year mortality in patients with ischemic stroke

Abstract

BackgroundPrior studies suggested that ischemic stroke patients with high omentin-1 concentrations were at a decreased risk of unstable carotid plaque and 3-month poor functional outcome. We aim to evaluate the association between serum omentin-1 and 1-y mortality after ischemic stroke. MethodsA total of 303 ischemic stroke patients were prospectively followed up at 1 y. Outcome was defined as death occurred during the follow-up period. A multivariable Cox model was used to evaluate the association between serum omentin-1 concentrations and 1-y mortality among ischemic stroke patients. ResultsFrom lowest to highest tertile of serum omentin-1, the 1-y cumulative death rate was 12%, 3.7% and 2.1%, respectively (P = 0.006). The hazard ratio (95% confidence interval) of the highest tertile compared with the lowest tertile was 0.19 (0.04–0.88) for mortality after multivariable adjustment (P for trend < 0.01). The net reclassification index and integrated discrimination improvement were significantly improved in predicting 1-y mortality when omentin-1 data was added to the multivariable Cox regression model. ConclusionsAmong patients with ischemic stroke, high baseline serum omentin-1 was associated with a decreased risk of 1-y mortality. These findings, if confirmed by clinical trials, suggest that increasing omentin-1 concentrations may lower the risk of mortality among ischemic stroke patients.